Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, MI.
Johns Hopkins University School of Medicine, Baltimore, MD.
Clin Gastroenterol Hepatol. 2023 Feb;21(2):546-548.e4. doi: 10.1016/j.cgh.2022.01.059. Epub 2022 Feb 17.
Multiple real-world studies have confirmed the safety and efficacy of hepatitis C (HCV) direct-acting antivirals (DAAs); however, few studies have provided data on long-term outcomes of patients without cirrhosis after achieving sustained virologic response (SVR). The aims of this analysis were to describe, among individuals in the PRIORITIZE Study achieving SVR: (1) the frequency of laboratory testing and imaging during long-term follow-up (LTFU), (2) changes in liver tests, (3) occurrence of hepatic decompensation or hepatocellular carcinoma (HCC) and deaths, and (4) durability of SVR.
多项真实世界研究证实了丙型肝炎（HCV）直接作用抗病毒药物（DAA）的安全性和有效性；然而，很少有研究提供关于无肝硬化患者实现持续病毒学应答（SVR）后的长期结局数据。本分析的目的在于描述 PRIORITIZE 研究中达到 SVR 的个体：（1）在长期随访（LTFU）期间实验室检测和影像学检查的频率；（2）肝功能检查的变化；（3）肝失代偿或肝细胞癌（HCC）和死亡的发生；以及（4）SVR 的持久性。
